ISSN: 2755-1059

Journal of Nephrology & Endocrinology Research

SCIENTIFIC Research and Community

Research Article

Open Access

Beyond Glycaemic Control in Diabetic Kidney Disease: Palm-Derived Tocotrienol-Rich Vitamin E as a Candidate Modulator of Oxidative, Glycation, Endothelial, and Renal-Metabolic Injury

Loso Judijanto

IPOSS Jakarta, Indonesia

ABSTRACT

Diabetic Kidney Disease (DKD) is driven by interconnected metabolic, haemodynamic, oxidative, inflammatory, endothelial, and fibrotic processes that persist despite improvements in glycaemic and blood-pressure management. Contemporary use of renin–angiotensin system blockade, sodium–glucose cotransporter-2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and glucagon-like peptide-1 receptor agonists has substantially improved cardiorenal outcomes, yet residual kidney risk remains. Palm oil is an important natural source of tocotrienols, vitamin E isoforms with antioxidant, anti-inflammatory, membrane-associated, and metabolic activities that differ from conventional α-tocopherol. This qualitative literature review examines the biological rationale and clinical evidence for palm-derived tocotrienol-rich vitamin E as a potential adjunctive nutritional intervention in DKD. Evidence is organised around four interacting domains: oxidative stress and mitochondrial dysfunction; advanced glycation and receptor-mediated injury; inflammation, endothelial dysfunction, and glomerular barrier disturbance; and renal metabolic, tubular, and lipotoxic injury. Small randomised studies have reported reductions in serum creatinine and corresponding increases in creatinine-based estimated glomerular filtration rate, but improvement in albuminuria and mechanistic biomarkers has not been consistently demonstrated. This endpoint discordance prevents current evidence from establishing structural renoprotection. Future trials should therefore evaluate tocotrienols against contemporary multidrug background therapy using eGFR slope, urinary albumin-to-creatinine ratio, cystatin C, tubular-injury biomarkers, redox and inflammatory biomarkers, and baseline vitamin-E status. Palm-derived tocotrienols remain biologically plausible but clinically unproven adjuncts requiring rigorous mechanism-informed trials.

***Corresponding author**

Loso Judijanto, IPOSS Jakarta, Indonesia.

Received: October 09, 2026; **Accepted:** October 14, 2026; **Published:** October 24, 2026

Keywords: Diabetic Kidney Disease, Tocotrienol-Rich Fraction, Palm Oil, Vitamin E, Oxidative Stress, Advanced Glycation End Products, Endothelial Dysfunction, Mitochondrial Dysfunction, Albuminuria; Renoprotection

JEL Classification Codes: I10; I12; I15; L65; Q16.

Introduction

Diabetic Kidney Disease (DKD) is among the most clinically consequential microvascular complications of diabetes mellitus and is a major contributor to Chronic Kidney Disease (CKD), kidney failure, cardiovascular morbidity, and premature mortality. Although persistent hyperglycaemia is an essential upstream driver, the natural history of DKD cannot be adequately explained by glucose exposure alone. Contemporary understanding instead conceptualizes DKD as a heterogeneous cardiorenal-metabolic disorder arising from interactions among altered intraglomerular haemodynamics, oxidative stress, mitochondrial dysfunction, advanced glycation, lipid accumulation, endothelial injury, inflammatory signalling, podocyte dysfunction, tubular stress, extracellular-matrix expansion, and progressive fibrosis [1-4]. This multidimensional pathogenesis helps explain why kidney disease may progress despite apparently satisfactory glycated haemoglobin concentrations and why albuminuria and estimated glomerular filtration rate (eGFR) do not always evolve in parallel. Some patients experience classical progression from glomerular hyperfiltration to increasing albuminuria and declining filtration, whereas others develop substantial eGFR deterioration with limited or absent albuminuria. Recognition of non-albuminuric DKD has therefore reinforced the need to phenotype kidney disease using complementary filtration, albuminuria, structural, and biomarker information rather than a single surrogate measure [5-7]. Consequently, a candidate renoprotective intervention should ideally be evaluated across several dimensions of kidney injury.

The therapeutic landscape has also changed fundamentally. Renin–angiotensin system (RAS) blockade remains important in albuminuric DKD, but sodium–glucose cotransporter-2 (SGLT2) inhibitors now provide kidney and cardiovascular protection extending beyond their glucose-lowering effect. DAPA-CKD and EMPA-KIDNEY demonstrated clinically relevant protection against CKD progression across broad populations, while finerenone has provided additional cardiorenal protection in patients with type 2 diabetes and CKD. More recently, the FLOW trial established kidney-outcome benefits with semaglutide in type 2 diabetes and CKD [8-13].

Nevertheless, substantial residual renal and cardiovascular risk remains after evidence-based therapy. This residual risk is partly attributable to persistent oxidative, inflammatory, fibrotic, mitochondrial, and metabolic abnormalities that may not be completely normalized by current pharmacotherapy [4]. Accordingly, interest has emerged in adjunctive interventions capable of influencing multiple pathophysiological pathways without replacing established disease-modifying medications.

Palm-Derived Tocotrienols as a Candidate Adjunct

Vitamin E comprises tocopherol and tocotrienol isoforms. Tocotrienols contain an unsaturated isoprenoid side chain that influences their distribution within lipid membranes and may contribute to biological activities distinct from those of α-tocopherol. Palm oil is one of the richest natural dietary sources of tocotrienols and commonly provides mixtures of α-, γ-, and δ-tocotrienol together with tocopherols. Experimental and clinical literature has associated tocotrienols with modulation of lipid peroxidation, inflammatory signalling, endothelial responses, lipid metabolism, and cellular stress pathways [14-17].

The direct clinical literature in DKD, however, remains limited. A foundational phase-IIa randomised trial reported lower serum creatinine and higher creatinine-derived eGFR after supplementation with a tocotrienol-rich vitamin-E preparation, with part of the creatinine signal remaining detectable after treatment withdrawal. Importantly, albuminuria, HbA1c, blood pressure, and several inflammatory or endothelial markers did not change in parallel [18]. A subsequent phase-IIb randomised trial similarly reported favourable creatinine/eGFR signals during follow-up but no convincing improvement in urinary albumin-to-creatinine ratio (UACR), transforming growth factor-β1 (TGF-β1), or vascular endothelial growth factor-A (VEGF-A) [19].

These findings create a scientifically important problem. A change in serum creatinine without concordant evidence from albuminuria, cystatin C, validated injury biomarkers, structural outcomes, or long-term eGFR slope cannot automatically be interpreted as structural kidney protection. The central research question should therefore move beyond whether tocotrienols "improve diabetic nephropathy" toward identifying which DKD pathways may plausibly be modified, which clinical signals have actually been demonstrated, and how those signals should be tested against modern standard-of-care therapy.

Research Questions and Objectives

This review is guided by five interrelated research questions. First, it asks through which oxidative, glycation, inflammatory, endothelial, mitochondrial, and metabolic mechanisms palm-derived tocotrienols could plausibly influence DKD. Second, it examines which renal signals have been demonstrated in human tocotrienol intervention studies and whether those signals appear independent of changes in glucose control or blood pressure. Third, it considers how discordance among serum creatinine, eGFR, albuminuria, and mechanistic biomarkers should be interpreted. Fourth, it evaluates how contemporary treatment with SGLT2 inhibitors, finerenone, GLP-1 receptor agonists, and RAS blockade changes the relevance of earlier tocotrienol trials. Fifth, it asks which trial design and biomarker strategy would be required to establish genuine additive renal protection.

Correspondingly, the objectives are to synthesise contemporary evidence on DKD pathophysiology and tocotrienol biology, critically evaluate the available renal clinical evidence, distinguish biological plausibility from demonstrated renoprotection, and establish a translational framework for future trials. Together, these objectives are intended to define a more rigorous evidentiary pathway from mechanistic promise to clinically meaningful kidney protection.

Literature Review: Conceptual and Theoretical Foundations

DKD as a Network Disease Rather Than an Isolated Glycaemic Complication

The classical glucose-centric model of diabetic complications has progressively evolved toward a network model in which metabolic, haemodynamic, inflammatory, oxidative, and fibrotic pathways reinforce each other. Hyperglycaemia increases intracellular metabolic flux, promotes formation of Reactive Oxygen Species (ROS), modifies proteins and lipids through glycation, perturbs mitochondrial energetics, and interacts with intrarenal haemodynamic stress. At the same time, obesity, insulin resistance, dyslipidaemia, and altered fatty-acid handling expose renal tissue to lipid-derived stress. These effects occur in glomerular endothelial cells, mesangial cells, podocytes, tubular epithelial cells, fibroblasts, and infiltrating immune cells [3-20].

This network model is particularly relevant to antioxidant interventions. If oxidative stress is only one node in a highly redundant pathological system, simply increasing systemic antioxidant capacity may be insufficient. Effective redox modulation would need either to affect several interconnected pathways or to intervene at a biologically important source of oxidative stress. This distinction partly explains why broad antioxidant supplementation has historically produced inconsistent clinical outcomes despite compelling preclinical evidence.

Oxidative Stress and NADPH Oxidase Signalling

Diabetic kidneys experience an imbalance between ROS generation and endogenous antioxidant defences. Major ROS-generating sources include mitochondria and nicotinamide adenine dinucleotide phosphate oxidases (NOX). Excessive ROS can oxidize membrane lipids, proteins, and nucleic acids and amplify inflammatory and profibrotic signalling. NOX-derived ROS also interact with endothelial nitric oxide signalling, thereby coupling oxidative stress to vascular dysfunction [21-24].

The nuclear factor erythroid 2-related factor 2 (NRF2)/Kelch-like ECH-associated protein-1 pathway regulates endogenous antioxidant responses. Disruption or inadequate activation of this pathway contributes to impaired redox resilience in DKD. NRF2-related mechanisms are therefore attractive targets because they represent modulation of cellular antioxidant defence rather than simple chemical scavenging of ROS [25-26].

Tocotrienols could theoretically influence this domain at several levels. Their lipid-soluble nature permits incorporation into membranes where lipid peroxidation occurs, while experimental literature suggests effects on redox-sensitive inflammatory pathways. Yet mechanistic plausibility cannot be equated with demonstrated intrarenal antioxidant activity in humans. The meta-analysis by [27]. is particularly instructive across randomised trials, supplementation did not consistently produce robust changes in systemic inflammatory and oxidative-stress biomarkers. This heterogeneity argues against assuming a uniform antioxidant effect in every clinical context.

Mitochondrial Dysfunction and Renal Metabolic Stress

The kidney is highly energy dependent, particularly within the

proximal tubule. Mitochondrial dysfunction can therefore disturb ATP production, fatty-acid oxidation, redox homeostasis, calcium regulation, mitophagy, mitochondrial fission and fusion, and cellular survival. Human and experimental DKD studies support abnormalities in several components of mitochondrial function, although the direction and timing of metabolic changes may vary across disease stages and renal cell types [28-33]. Recent work further emphasises that mitochondrial dysfunction is intertwined with immunometabolic remodelling, suggesting that redox, inflammatory, and energetic abnormalities should be interpreted as interacting processes rather than isolated mechanisms [31].

Mitochondrial stress also intersects with lipid accumulation. When fatty-acid uptake and synthesis exceed oxidative disposal, toxic lipid intermediates can accumulate in glomerular and tubular cells, promoting endoplasmic-reticulum stress, inflammation, insulin resistance, apoptosis, and fibrosis. Lipotoxicity therefore provides an important conceptual bridge between systemic metabolic dysfunction and intrarenal injury [20].

Thioredoxin-Interacting Protein (TXNIP) constitutes another link among glucose toxicity, ROS, autophagy, mitochondrial dysfunction, and inflammatory activation. Increased TXNIP signalling has been implicated in diabetic tissue injury and may interact with inflammasome activation [34]. A putative intervention capable of reducing membrane oxidation or improving mitochondrial stress responses could therefore produce renal effects without substantially reducing HbA1c, although this remains a hypothesis requiring direct confirmation.

Advanced Glycation and RAGE-Mediated Injury

Persistent hyperglycaemia promotes non-enzymatic reactions among reducing sugars and amino groups in proteins, lipids, and nucleic acids, ultimately generating advanced glycation end products (AGEs). AGEs can directly alter extracellular-matrix proteins and vascular properties, while binding to the receptor for advanced glycation end products activates NF-κB and other signalling pathways that intensify ROS formation, cytokine production, endothelial dysfunction, and fibrosis [35-36].

The AGE axis is relevant to DKD because the kidney is both affected by and involved in the clearance of glycation products. Reduced kidney function can further increase AGE burden, potentially creating a bidirectional relationship between glycation and CKD. Dietary AGE exposure and endogenous AGE formation may therefore interact with the metabolic environment of diabetes [36].

Tocotrienols should not currently be described as proven anti-glycation therapy. A more defensible hypothesis is that antioxidant and membrane-protective actions could reduce downstream amplification of AGE-associated oxidative and inflammatory signalling. Direct human demonstration that palm tocotrienols reduce renal AGE accumulation, circulating AGE-RAGE activity, or tissue glycation in DKD remains insufficient.

Inflammation, NLRP3 Activation, and Tubulointerstitial Injury

Chronic low-grade inflammation has become a central component of contemporary DKD models. Hyperglycaemia, AGEs, oxidized lipids, mitochondrial ROS, cellular debris, and haemodynamic stress stimulate transcription factors and innate immune pathways that increase cytokines and chemokines. TNF-related signalling, IL-6, MCP-1, and other inflammatory mediators are associated with kidney injury and progression [37-38].

The NLRP3 inflammasome represents an important intersection between metabolic danger signals and inflammatory cell death. Its activation can promote caspase-related cytokine processing and pyroptosis, potentially contributing to glomerular as well as tubular damage. Oxidative stress, mitochondrial perturbation, and TXNIP signalling can provide activating signals, making the inflammasome relevant to a network-based model of DKD [34-40].

Tubulointerstitial injury deserves particular emphasis because conventional DKD discussions have historically focused on glomerular lesions and albuminuria. The tubular compartment is metabolically demanding and continuously exposed to filtered glucose, proteins, inflammatory mediators, and altered oxygen requirements. Tubular hypoxia, mitochondrial abnormalities, immune-cell recruitment, and fibroblast activation may substantially influence long-term eGFR loss [41].

Endothelial Dysfunction and the Glomerular Filtration Barrier

The glomerular filtration barrier is an integrated system composed of fenestrated endothelial cells, endothelial glycocalyx, glomerular basement membrane, and podocytes. Hyperglycaemia, ROS, AGEs, altered VEGF signalling, and inflammatory activation can disrupt the endothelial glycocalyx, reduce nitric oxide bioavailability, and impair communication between podocytes and endothelial cells [42-43].

This endothelial dimension creates a mechanistic rationale for evaluating adhesion molecules and vascular markers in tocotrienol trials. Tocotrienols have been reported to affect inflammatory and endothelial pathways in experimental and non-DKD settings, but clinical renal trials have not established normalization of endothelial dysfunction as the mechanism underlying creatinine changes. The absence of consistent change in measured markers such as VCAM-1 in early DKD supplementation research is therefore important negative evidence rather than a minor detail.

Contemporary Disease-Modifying Therapy as the New Background Standard

The biological rationale for a nutritional adjunct cannot be evaluated independently of the pharmacological environment in which patients now receive treatment. RAS inhibition is complemented by SGLT2 inhibition, which can reduce intraglomerular pressure and alter tubular energetics and oxygen demand while providing robust protection against CKD progression. DAPA-CKD and EMPA-KIDNEY transformed the treatment landscape, while CREDENCE established kidney protection with canagliflozin in diabetic albuminuric CKD [8-46].

Finerenone targets mineralocorticoid-receptor-mediated inflammatory and fibrotic pathways. FIDELIO-DKD, FIGARO-DKD, and the pooled FIDELITY analysis demonstrate that its benefits extend across clinically relevant cardiorenal outcomes [9-47].

GLP-1 receptor agonists constitute another major change. Earlier evidence suggested cardiovascular and possible kidney benefits, while FLOW directly demonstrated improved kidney outcomes with semaglutide in patients with type 2 diabetes and CKD. Meta-analytic evidence has further strengthened the kidney-outcome rationale for this drug class [48-50].

Thus, an intervention evaluated before widespread use of these agents cannot automatically be assumed to offer incremental benefit when added to contemporary layered treatment. The relevant translational question is now whether tocotrienols can

provide additional biological or clinical protection after established pathways have already been modified by evidence-based therapy [51-52].

Method

Review Design

This article employed a Qualitative Literature Review (QLR) rather than a systematic literature review or meta-analysis. The purpose was explanatory and integrative: to connect mechanistic, translational, biomarker, and clinical trial literature into a coherent framework for evaluating palm-derived tocotrienol-rich vitamin E in DKD.

Accordingly, the methodology did not seek exhaustive study capture, statistical pooling, formal risk-of-bias scoring, or PRISMA-based study selection. Literature was instead purposively selected for relevance to the predefined conceptual domains: DKD mechanisms, tocotrienol biology, tocotrienol clinical intervention evidence, renal biomarkers, and contemporary disease-modifying DKD therapy.

Literature Identification and Scope

The principal literature window was 2020–2026 to emphasize current mechanistic understanding and the rapidly evolving therapeutic environment. Relevant publications were identified through PubMed/MEDLINE, Scopus-oriented journal searches, publisher databases, and cross-referencing of recent peer-reviewed reviews and trials. Search concepts included combinations of diabetic kidney disease, diabetic nephropathy, tocotrienol, tocotrienol-rich fraction, palm vitamin E, oxidative stress, NADPH oxidase, NRF2, mitochondrial dysfunction, advanced glycation end products, RAGE, endothelial dysfunction, NLRP3, tubular injury, albuminuria, eGFR, cystatin C, kidney biomarkers, SGLT2 inhibitor, finerenone, and GLP-1 receptor agonist.

One pre-2020 randomised study was retained as a deliberate exception because it constitutes the foundational phase-IIa clinical trial directly evaluating tocotrienol-rich vitamin E in diabetic nephropathy [18]. It was not counted toward the requirement for contemporary 2020-2026 literature.

Qualitative Thematic Synthesis

Evidence was synthesized into four primary mechanistic domains:

- oxidative stress and mitochondrial dysfunction
- advanced glycation and RAGE-associated signalling
- inflammation, endothelial dysfunction, and glomerular microvascular injury
- renal metabolic, tubular, and lipotoxic injury. Clinical evidence was then evaluated separately to avoid treating mechanistic plausibility as proof of patient-level efficacy.

Special emphasis was placed on endpoint concordance. Changes in creatinine-derived eGFR were compared conceptually with UACR, inflammatory or endothelial biomarkers, and evidence of durable kidney benefit. Finally, older tocotrienol evidence was reinterpreted in the context of modern layered DKD therapy.

Results: Thematic Findings

Theme 1: Oxidative-Stress Regulation Is Biologically Plausible but Not Yet Clinically Demonstrated in DKD

Oxidative stress remains one of the strongest biological rationales for investigating tocotrienols. In diabetes, mitochondrial electron transport abnormalities, NOX activity, AGE-RAGE signalling, inflammation, and lipid overload can all elevate ROS production. These processes oxidize membrane lipids and propagate injury through endothelial, glomerular, and tubular compartments [21-24].

Tocotrienols are particularly interesting because their antioxidant behaviour occurs in lipid environments in which membrane lipid peroxidation is relevant. Reviews of tocotrienol pharmacology also describe effects involving inflammatory transcription, lipid metabolism, endothelial signalling, and cellular stress responses, indicating a broader biological profile than simple ROS scavenging [14-17].

However, clinical evidence remains heterogeneous. The randomised trial by [53] in type 2 diabetes reported favourable changes in glycaemic, oxidative, and inflammatory parameters with δ-tocotrienol. Such results provide proof that tocotrienols can affect systemic metabolic biology in humans, but they cannot be directly translated into structural renal protection.

More importantly, the meta-analysis by [24]. found that tocotrienol supplementation did not produce universally consistent reductions across commonly measured inflammatory and oxidative markers. Differences in formulation, isoform composition, dose, population, baseline antioxidant status, duration, and biomarker selection may contribute to heterogeneity.

This distinction is essential for DKD. Oxidative stress is compartmentalized, and circulating malondialdehyde or CRP may not accurately capture redox conditions in podocytes, glomerular endothelium, or tubular epithelium. Future studies should combine systemic biomarkers with renal injury markers and, where possible, mechanistically proximal indicators of redox activity.

Figure 1 summarizes the proposed mechanistic network linking diabetic metabolic stress to kidney injury and identifies the sites at which tocotrienol-rich vitamin E could theoretically act. The figure deliberately distinguishes **established DKD pathways** from **hypothesized tocotrienol intervention points**, because direct human evidence for many of these renal mechanisms is not yet available.




Figure 1: Integrated DKD Pathobiology and Hypothesized Tocotrienol Targets

The figure illustrates why a single biomarker is unlikely to establish mechanism. If tocotrienols primarily alter membrane oxidation, for example, downstream inflammatory changes may depend on baseline disease activity and concomitant therapy. Conversely, an improvement in creatinine-derived eGFR without concordant evidence across this network leaves open several alternative explanations. The central translational task is therefore to demonstrate pathway engagement and kidney benefit simultaneously.

Theme 2: Mitochondrial and Renal-Metabolic Protection Is an Important but Understudied Hypothesis

Mitochondrial abnormalities have been identified across experimental and human DKD literature, affecting oxidative phosphorylation, ROS generation, mitochondrial dynamics, mitophagy, and biogenesis. A systematic review of human data identified evidence supporting mitochondrial dysfunction in DKD, while more recent mechanistic analyses emphasise mitochondrial quality control, metabolic reprogramming, and immunometabolism as related therapeutic domains [28-33]. These observations strengthen the rationale for testing pathway-specific biomarkers rather than inferring mitochondrial protection from changes in serum creatinine alone.

Tocotrienols could theoretically protect mitochondrial membranes against lipid oxidation or indirectly improve mitochondrial homeostasis by reducing redox-sensitive inflammatory signalling. Nevertheless, demonstrating antioxidant action in a non-renal tissue or cell model is not sufficient to establish mitochondrial renoprotection.

Renal lipid metabolism is equally relevant. DKD occurs in an environment of insulin resistance and altered fatty-acid handling, and renal lipotoxicity can promote mitochondrial stress, endoplasmic-reticulum dysfunction, apoptosis, and fibrosis [20]. Experimental evidence also indicates that mitochondrial oxidative damage can reprogramme lipid metabolism in renal tubular epithelial cells, reinforcing the mechanistic link between redox injury and tubular lipotoxicity [54]. Because tocotrienols have biological interactions with lipid-metabolic pathways, their potential effects on renal lipotoxicity merit investigation. Yet the existing DKD trials did not include comprehensive renal lipidomic or metabolomic endpoints.

An informative future trial could therefore incorporate targeted metabolomics, acylcarnitine profiles, markers of fatty-acid oxidation, urinary mitochondrial DNA, and validated urinary tubular markers. Contemporary metabolomic research suggests that multiple interconnected metabolic pathways may provide useful DKD biomarker information, although assay standardisation and prospective validation remain necessary before routine clinical use (Das et al., 2024). Such approaches would test the proposition of "renal metabolic protection" directly rather than infer it from changes in serum creatinine.

Theme 3: Tocotrienols Could Intersect with AGE-Driven Injury, but Direct Anti-Glycation Evidence Is Limited

AGE accumulation provides a mechanistic bridge among chronic hyperglycaemia, oxidative stress, inflammation, endothelial dysfunction, and fibrosis. AGE-RAGE signalling can activate NF-κB and increase ROS generation, while chemically modified extracellular proteins may alter vascular and glomerular structure [35-36].

Tocotrienols are frequently described as antioxidants and anti-inflammatory compounds, making downstream attenuation of AGE-associated oxidative signalling plausible. However, current clinical evidence does not establish that tocotrienol-rich vitamin E reduces AGE formation or RAGE signalling in patients with DKD. This distinction prevents overextension of preclinical mechanistic reasoning.

Future studies should therefore measure selected AGE species, soluble RAGE-related biomarkers, oxidative glycation products, and possibly skin autofluorescence alongside conventional renal outcomes. A mechanistic trial could then determine whether any renal effect is associated with modification of glycation biology.

Theme 4: Inflammation and Endothelial Dysfunction Offer Plausible Targets but Clinical Signals Are Inconsistent

Inflammation in DKD extends from cytokine signalling to inflammasome activation, immune-cell recruitment, and fibrotic remodelling. TNF-related pathways, MCP-1, IL-6, NF-κB signalling, NLRP3 activation, and pyroptotic processes have all been implicated in progression [37-40].

Endothelial injury is closely integrated with these processes. Damage to the glomerular endothelial glycocalyx, altered nitric oxide activity, oxidative stress, and disturbed podocyte–endothelial communication may impair filtration-barrier integrity [42-43].

The relevance to tocotrienol supplementation is conceptually strong because tocotrienols have been associated with modulation of redox-sensitive inflammatory and vascular pathway [15-17]. Yet the direct DKD clinical evidence remains less convincing at the biomarker level. In the phase-IIa trial, markers such as TNFR1 and VCAM-1 were not uniformly improved despite the creatinine/eGFR signal [18].

This mismatch could have several explanations. The biomarkers may have been insufficiently sensitive; treatment duration may have been inadequate; kidney-specific effects may not be captured systemically; or the renal filtration signal may not have represented substantive modification of inflammatory or structural disease. Each explanation is plausible, meaning that none should be assumed without additional evidence.

Theme 5: Tubular Injury Requires Greater Attention

DKD is not exclusively a glomerular disease. Tubular cells experience high metabolic demand and are exposed to glucose, albumin, oxidized molecules, altered oxygen tension, and inflammatory mediators. Tubulointerstitial inflammation and fibrosis contribute substantially to progressive functional decline [41].

Contemporary biomarker research provides tools to interrogate this compartment. KIM-1, NGAL, MCP-1, YKL-40, IL-18 and other urinary biomarkers may provide information beyond creatinine and albuminuria in selected research settings. Reviews also emphasize emerging multi-marker and multi-omics approaches for characterizing DKD phenotypes [5-56].

In VA NEPHRON-D biomarker analyses, several urinary markers of tubular health were associated with subsequent adverse outcomes, illustrating the potential value of measuring tubular biology in interventional studies [57]. TNFR1 and TNFR2 are likewise relevant to inflammatory risk stratification, although their interpretation is complex and is influenced by kidney function and renal handling [58-59].

For tocotrienols, this means that a future trial should not be restricted to serum creatinine and UACR. Demonstration of reduced KIM-1, MCP-1, NGAL, or another validated injury signature alongside favourable eGFR trajectory would substantially strengthen a causal renoprotective interpretation.

Theme 6: The Human Tocotrienol Evidence Contains a Renal Signal, but Endpoint Discordance Is the Central Limitation

The foundational phase-IIa study deserves attention because it generated the hypothesis that tocotrienol-rich vitamin E might influence kidney function in diabetic nephropathy. Supplementation was associated with lower serum creatinine and higher calculated eGFR relative to placebo, with some creatinine differences reportedly detectable after treatment withdrawal. At the same time, HbA1c, blood pressure, UACR, malondialdehyde, TNFR1, VCAM-1, and thromboxane B2 did not demonstrate a uniformly concordant treatment response [18].

The subsequent phase-IIb trial by [19] extended treatment and again reported favourable changes in creatinine and creatinine-based eGFR at selected time points, including a notable response among participants with stage-3 CKD. However, UACR did not significantly improve, and measured TGF-β1 and VEGF-A responses did not establish a convincing antifibrotic or vascular mechanism.

These results justify continued research because replication of a creatinine signal across related trials is more informative than an isolated exploratory observation. However, the same results are insufficient to establish structural renoprotection because serum creatinine is influenced by filtration as well as creatinine generation and handling. Furthermore, calculated eGFR based on serum creatinine is not an independent outcome: if creatinine falls, creatinine-based eGFR necessarily rises.

The discordance between filtration estimates and other renal outcomes is therefore not a peripheral limitation; it is the pivotal evidentiary issue. Figure 2 presents an "evidence ladder" that separates preliminary renal-function-related signals from increasingly definitive evidence of structural or clinical kidney benefit. This hierarchy makes clear that creatinine-based changes require confirmation by independent filtration measures, albuminuria, injury biomarkers, eGFR slope, and ultimately clinically meaningful kidney outcomes.




Figure 2: Current Tocotrienol Evidence Ladder in DKD

The clinical interpretation is therefore asymmetric. The trials are strong enough to generate a hypothesis that tocotrienol supplementation changes a renal-function-related measure, but not strong enough to demonstrate that nephron loss, glomerular barrier injury, tubular damage, or fibrosis has been slowed. This distinction should guide both academic language and future trial design.

Theme 7: Tocotrienol Formulation, Bioavailability, and Baseline Vitamin-E Status May Matter

Tocotrienols are not pharmacologically interchangeable with tocopherols, nor are all tocotrienol formulations equivalent. Isoform composition, food intake, delivery matrix, dose, absorption, and competition among vitamin-E compounds may influence exposure. Human pharmacokinetic literature demonstrates substantial formulation and bioavailability considerations [60].

The systematic review of randomised palm tocotrienol-rich fraction trials by [16] illustrates both the breadth of clinical investigation and substantial heterogeneity across populations, formulations, outcomes, and durations. This heterogeneity reinforces the need to report the exact composition of tocotrienol preparations rather than use “vitamin E” as a generic intervention label.

Baseline nutritional status may also modify response. The exploratory observation that participants with lower baseline vitamin-E concentrations could experience differential responses in early DKD work is biologically interesting but requires prospective confirmation. Future trials should therefore prespecify baseline circulating tocopherol and tocotrienol measurements and, if sufficiently powered, evaluate interaction by baseline status.

Theme 8: Contemporary Standard-of-Care Therapy Changes the Research Question

A major weakness in extrapolating earlier tocotrienol studies is that they were conducted before contemporary multidrug DKD therapy became routine. Current treatment increasingly layers RAS blockade, SGLT2 inhibition, finerenone when indicated, and GLP-1 receptor agonist therapy according to phenotype, comorbidity, kidney function, albuminuria, and tolerability.

DAPA-CKD and EMPA-KIDNEY established SGLT2 inhibitors as foundational kidney-protective therapies, while follow-up of EMPA-KIDNEY has further strengthened evidence for durable cardiorenal benefits [8-61]. Canagliflozin analyses similarly demonstrate benefit across clinically relevant kidney-function and albuminuria categories [44-45].

Finerenone targets a partially distinct inflammatory and fibrotic axis, with FIDELITY demonstrating benefits across the combined FIDELIO-DKD and FIGARO-DKD populations (Bakris et al., 2020; Pitt et al., 2021; Agarwal et al., 2022). Meanwhile, FLOW provides direct kidney-outcome evidence for semaglutide, complementing earlier mechanistic and cardiovascular evidence for GLP-1 receptor agonists.

Consequently, the modern question is not whether tocotrienols outperform placebo under historical background therapy. The important question is whether they add measurable biological or clinical benefit after contemporary standard-of-care therapy has reduced haemodynamic, metabolic, inflammatory, and fibrotic risk.

This shift is shown in Figure 3, which positions tocotrienol-rich vitamin E outside the established treatment hierarchy and explicitly classifies it as an investigational adjunct. Its placement below residual renal risk emphasises that tocotrienols should be tested as an addition to, rather than a replacement for, therapies with established kidney-outcome benefits.




Figure 3: Positioning Tocotrienols within Contemporary DKD Management

This framework prevents a common interpretive error: positioning a nutraceutical with preliminary evidence as an alternative to therapies supported by large kidney-outcome trials. The scientifically defensible role of tocotrienols at present is exploratory and adjunctive.

Discussion and Analysis

Reframing the Primary Question

The literature supports reframing the field away from the binary question, "Do tocotrienols improve diabetic nephropathy?" That question is overly broad because DKD encompasses multiple phenotypes and because "improvement" can refer to serum biomarkers, albuminuria, kidney function trajectory, structural injury, or hard renal events. A more precise question is which renal pathophysiological domains palm-derived tocotrienols can modify when administered to patients already receiving contemporary standard-of-care DKD therapy, and whether those modifications translate into slower kidney disease progression. This reformulation separates mechanism from efficacy while recognising that modern patients are treated differently from participants enrolled in earlier tocotrienol studies.

Why the Creatinine/eGFR Signal Should Not Be Dismissed—or Overinterpreted

The repeated creatinine/eGFR observations in the early randomised studies deserve further investigation. Dismissing them completely would ignore potentially informative clinical signals. At the same time, interpreting them as definitive "kidney recovery" would exceed the evidence.

Creatinine-based eGFR is mathematically dependent on serum creatinine. A reduction in creatinine therefore increases calculated eGFR even if the underlying mechanism is unrelated to structural nephron protection. Potential explanations include genuine improvement in filtration, haemodynamic effects, altered creatinine generation, altered tubular handling, dietary or metabolic changes, or random variation.

A future trial can resolve much of this uncertainty by measuring serum creatinine and cystatin C simultaneously and applying combined creatinine-cystatin C eGFR equations. Contemporary CKD-EPI work has shown that equations combining creatinine and cystatin C can improve GFR estimation and provide an important independent check on creatinine-only estimates [62]. Direct GFR measurement in a mechanistic substudy would provide still stronger validation, while repeated measurements would help distinguish a short-term functional shift from a durable change in eGFR slope.

UACR should remain a core endpoint because albuminuria reflects clinically relevant glomerular-barrier pathology and is independently associated with outcomes. However, the recognised non-albuminuric DKD phenotype means that lack of UACR improvement cannot, by itself, exclude all kidney benefit [2-6]. The appropriate response to endpoint discordance is therefore multidimensional measurement, not preferential selection of whichever endpoint gives the most favourable result. Concordance across filtration, albuminuria, tubular injury, and mechanistic biomarkers would provide a more persuasive basis for causal interpretation.

Biomarkers Could Convert an Ambiguous Clinical Signal into a Mechanistic Finding

The most efficient next research step may not be an immediate large outcome trial. Instead, a well-designed phase-II mechanistic study could establish whether tocotrienols engage relevant renal pathways. This staged approach would reduce the risk of advancing to an expensive outcome trial before biological target engagement and endpoint concordance have been demonstrated.

The biomarker panel should contain complementary domains rather than numerous redundant markers. UACR and creatinine/cystatin-C eGFR would capture established clinical dimensions. Urinary KIM-1, NGAL, MCP-1, YKL-40 or similar markers could assess tubular injury or inflammatory stress. Plasma TNFR1/TNFR2 may provide information on systemic and kidney-related inflammatory risk, although filtration and renal handling must be considered when interpreting changes [55-59].

Redox measurement poses a greater challenge. Single systemic oxidative-stress markers are often nonspecific and vulnerable to methodological variation. A combination of lipid-peroxidation products, antioxidant status, and pathway-related measurements could be more informative. Baseline and on-treatment plasma concentrations of tocotrienol isoforms are also necessary to document exposure.

Recent biomarker research increasingly moves beyond single-marker models toward multimarker signatures, proteomic and metabolomic phenotyping, and integrated multi-omics approaches [5-63]. Multi-omics studies have begun to identify candidate molecular signatures that may complement traditional eGFR and albuminuria measures, although external validation and clinical utility remain important limitations [63-64]. Such approaches are particularly appropriate for a candidate compound hypothesised to influence several interconnected biological systems.

The Four Mechanistic Domains Are Interdependent

The thematic framework developed in this review should not be interpreted as four independent mechanisms. Oxidative stress promotes AGE-RAGE signalling and endothelial dysfunction; AGE-RAGE activation generates additional oxidative and inflammatory signals; mitochondrial dysfunction can activate inflammatory pathways; inflammation worsens endothelial and tubular injury; and altered lipid metabolism further impairs mitochondria.

This interconnectedness is both an opportunity and a challenge for tocotrienol research. A compound with pleiotropic redox, lipid, membrane, and inflammatory actions might influence several nodes at once. Conversely, modest effects spread across multiple pathways can be difficult to detect and may fail to produce clinically meaningful kidney protection.

The proper scientific strategy is therefore to avoid claiming mechanistic breadth simply because numerous pathways are biologically plausible. Demonstration should proceed sequentially from exposure, to pathway engagement, to validated renal biomarkers, to kidney function trajectory, and ultimately to clinically meaningful outcomes.

Tocotrienol-Specific Issues Require Better Standardization

Future studies should describe the tested product in sufficient detail to permit replication. “Vitamin E” is inadequate because vitamin-E formulations can differ markedly in tocopherol and tocotrienol composition. At minimum, studies should report the quantity of each tocotrienol isoform, accompanying tocopherol concentrations, total daily dose, delivery formulation, timing with food, adherence, and circulating exposure [16-60].

This issue also affects interpretation of the broader tocotrienol literature. Effects reported for purified δ-tocotrienol cannot automatically be generalized to palm tocotrienol-rich fraction, and effects of mixed tocotrienol formulations cannot automatically be attributed to a single isoform.

Likewise, dose escalation should not be assumed to produce greater benefit. Pharmacokinetics, tissue distribution, absorption, and interaction among vitamin-E isoforms may be nonlinear. Dose selection should therefore be supported by pharmacokinetic and biomarker data.

Baseline Vitamin-E Status as a Candidate Precision-Nutrition Variable

A particularly interesting hypothesis arising from early DKD research is that baseline vitamin-E status may modify treatment response. This is compatible with a precision-nutrition framework: supplementation might provide greater biological benefit in participants with lower baseline tocotrienol/tocopherol exposure or greater oxidative burden than in well-nourished individuals.

However, post hoc subgroup signals are vulnerable to chance. A future trial should prespecify baseline vitamin-E status and test effect modification formally. Dietary assessment would also be valuable because palm oil intake, other dietary vitamin-E sources, antioxidant supplementation, and food quality may substantially influence exposure.

This approach would help answer whether tocotrienols should be conceptualised as general pharmacological-dose nutraceuticals or as targeted supplementation for biologically defined subgroups. It would also help determine whether baseline nutritional status functions as a treatment-effect modifier rather than merely a descriptive covariate.

Interaction with SGLT2 Inhibition Is a Priority Research Question

SGLT2 inhibitors alter glomerular haemodynamics, tubular sodium and glucose handling, oxygen demand, and metabolic physiology in ways that may overlap with the proposed renal-metabolic actions of tocotrienols. They also reduce major clinical kidney outcomes, making them difficult to omit ethically from trials in eligible patients (Heerspink et al., 2020; EMPA-KIDNEY Collaborative Group, 2023; Zou et al., 2024).

This overlap raises competing hypotheses. Tocotrienols might produce additive benefit by addressing residual lipid peroxidation and inflammatory stress not fully suppressed by SGLT2 inhibition. Alternatively, part of the biological pathway available for

modification in earlier trials may already be attenuated by modern therapy, reducing incremental benefit.

The same argument applies to finerenone and semaglutide. Finerenone directly targets pathways related to inflammation and fibrosis, while GLP-1 receptor agonists improve metabolic and cardiorenal outcomes. Tocotrienol trials must therefore assess background therapy carefully and, where feasible, stratify randomisation according to SGLT2 inhibitor and finerenone use.

Proposed Design for the Next Clinical Trial

A rational next trial would enroll adults with type 2 diabetes and persistent CKD who are receiving stable guideline-directed care. Participants would ideally have an eGFR range broad enough to examine moderate CKD but sufficiently stable to permit meaningful slope estimation. Enrichment for persistent albuminuria could improve event and biomarker sensitivity, although a non-albuminuric stratum could be informative.

Randomization should be stratified according to baseline eGFR, UACR, SGLT2 inhibitor use, finerenone use, GLP-1 receptor agonist use, and baseline vitamin-E status. Stable RAS blockade should be expected when clinically indicated.

An intervention duration of at least 12 months would be preferable for mechanistic work, with longer follow-up required for eGFR-slope analysis. A brief trial may detect biomarker shifts but cannot establish durable modification of DKD progression.

Figure 4 translates the review findings into a proposed next-generation trial architecture designed specifically to resolve the ambiguities of earlier studies. The design links background therapy, baseline phenotyping, stratified randomisation, longitudinal follow-up, and concordant renal-mechanistic endpoints so that a filtration signal can be tested against independent evidence of pathway engagement and kidney injury.




Figure 4: Proposed Mechanism-Informed Trial of Palm Tocotrienols in Contemporary DKD

Such a trial would substantially improve causal inference. A favourable result across creatinine- and cystatin-C-derived filtration, UACR or tubular biomarkers, and relevant mechanistic markers would provide much stronger evidence than an isolated change in creatinine. Conversely, absence of biomarker and slope effects would appropriately weaken the renoprotection hypothesis even if short-term creatinine differences were observed.

Safety, Clinical Translation, and the Risk of Premature Therapeutic Claims

The available literature generally portrays tocotrienols as tolerable in studied populations, but safety needs to be specifically evaluated in CKD. Reduced renal function frequently coexists with polypharmacy, cardiovascular disease, altered nutritional status, and changes in drug handling. Future trials should therefore systematically record adverse events, liver function, electrolyte changes, bleeding events where relevant, and potential interactions with concurrent medication.

The strongest translational message from the current evidence is consequently not that patients with DKD should begin tocotrienol supplementation. Rather, it is that palm-derived tocotrienols possess sufficient biological plausibility and preliminary human renal signals to justify appropriately designed clinical investigation.

This distinction is particularly important because nutraceutical evidence is vulnerable to extrapolation. "Natural source," "antioxidant," and "vitamin" do not establish clinical efficacy. Large contemporary DKD trials have set a substantially higher evidentiary standard for claims of renoprotection.

Agricultural and Nutritional Relevance of Palm-Derived Tocotrienols

Palm-derived tocotrienols also have a broader translational dimension. Palm oil is an established agricultural commodity and an important source from which tocotrienol-rich fractions can be recovered and standardised. If future clinical evidence confirms a meaningful benefit, value-added nutritional or pharmaceutical applications could diversify the utilisation of palm-derived bioactives.

However, agricultural availability should not be allowed to drive therapeutic inference. Clinical development must remain based on pharmacological characterization, purity, reproducibility, safety, biological pathway engagement, and patient outcomes. Product standardisation is particularly important because differences in refining, extraction, isoform composition, and formulation can influence the biological properties of the final tocotrienol preparation [15-17].

Conclusion

Diabetic kidney disease is produced by interacting metabolic, haemodynamic, oxidative, glycation, inflammatory, endothelial, mitochondrial, tubular, and fibrotic processes. This complexity provides a plausible biological rationale for investigating interventions capable of modifying several disease pathways simultaneously.

Palm-derived tocotrienol-rich vitamin E is an intriguing candidate because tocotrienols possess physicochemical and biological properties that distinguish them from conventional α-tocopherol and because preliminary randomised trials have reported favourable serum-creatinine and creatinine-based eGFR signals. Nevertheless, those signals have not been consistently accompanied by improvements in albuminuria, inflammatory or endothelial markers, or other evidence establishing structural renal protection.

The existing evidence should therefore be characterised as hypothesis-generating rather than practice-changing. Creatinine/eGFR discordance with UACR is a central knowledge gap and must be resolved before tocotrienols can reasonably be described as renoprotective.

The most important future advance would be a mechanism-informed randomised trial conducted on top of contemporary guideline-directed DKD treatment. Such a study should incorporate eGFR slope, creatinine–cystatin-C assessment, UACR, tubular-injury biomarkers, redox and inflammatory measurements, tocotrienol exposure, baseline vitamin-E status, and stratification by modern therapies. Concordance across these domains would provide a scientifically credible bridge from biological plausibility to clinical renal protection.

Until such evidence becomes available, palm-derived tocotrienol-rich vitamin E should be considered a promising but unproven adjunctive strategy whose principal value lies in generating a testable research programme focused on the residual metabolic and inflammatory risk that remains in contemporary DKD. Future research should therefore prioritise mechanistic validation, endpoint concordance, safety, and additive benefit on top of evidence-based therapy before any practice-changing claims are made.

References

1. Selby NM, Taal MW (2020) An updated overview of diabetic nephropathy Diagnosis, prognosis treatment goals and latest guidelines. Diabetes Obesity and Metabolism 22: 3-15.
2. Ricciardi CA Gnudi L (2021) 'Kidney disease in diabetes From mechanisms to clinical presentation and treatment strategies. Metabolism 124: 154890.
3. Woodhams L, Sim TF, Chalmers L, Yeap B, Green D, et al. (2021) Diabetic kidney disease in type 2 diabetes A review of pathogenic mechanismsn patient-related factors and therapeutic options PeerJ 9: e11070.
4. Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, et al. (2022) Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney International 102: 248-260.
5. Liu H, Feng J, Tang L (2022) 'Early renal structural changes and potential biomarkers in diabetic nephropathy.Frontiers in Physiology 13: 1020443.
6. Scilletta S, Di Marco M, Miano N, Filippello A, Di Mauro S, et al. (2023) 'Update on diabetic kidney disease (DKD) Focus on non-albuminuric DKD and cardiovascular risk. Biomolecules 13 :5-752.
7. Rroji M, Bob F, Lo Cicer L, Figurek A, Spasovski G, et al. (2026) Biomarkers in diabetic kidney disease Early detection prognostic assessment and integration with multi-omics signatures. Life 16: 1164
8. Heerspink HJL, Stefánsson BV, Correa Rotter R, Chertow GM, Greene T, et al. (2020) Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine 383: 1436-1446.
9. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, et al. (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. New England Journal of Medicine 383: 2219-2229.
10. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, et al. (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. New England Journal of Medicine 385: 2252-2263.
11. De Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, et al. (2022) Diabetes management in chronic kidney disease a consensus report by the American Diabetes Association and Kidney Disease Improving Global Outcomes. Kidney International 102: 974-989.
12. EMPA-KIDNEY Collaborative Group (2023) Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine 388: 117-127.
13. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, et al. (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New England Journal of Medicine 391: 109-121.
14. Wong SK, Kamisah Y, Mohamed N, Muhammad N, Masbah N, et al. (2020) Potential role of tocotrienols on non-communicable diseases A review of current evidence. Nutrients 12: 259.
15. Zainal Z, Khaza'ai H, Radhakrishnan AK, Chang SK

(2022) Therapeutic potential of palm oil vitamin E-derived tocotrienols in inflammation and chronic diseases Evidence from preclinical and clinical studies. Food Research International156: 111175.

16. Looi AD, Palanisamy UD, Moorthy M, Radhakrishnan AK (2025) Health benefits of palm tocotrienol-rich fraction A systematic review of randomized controlled trials. Nutrition Reviews 83: 307-328.
17. Ali M, Sheikh Abdul Kadir SH, Ibrahim E, Albaraikan A (2026) Tocotrienol-rich fraction of vitamin E in diabetes and cardiovascular disease From molecular mechanisms to clinical application. International Journal of Cardiology Cardiovascular Risk and Prevention 30: 200686.
18. Tan GCJ, Suzanne May Quinn Tan, Sonia Chew Wen Phang, Yeek Tat Ng, En Yng Ng, et al. (2019) Tocotrienol-rich vitamin E improves diabetic nephropathy and persists 6-9 months after washout A phase IIa randomized controlled tria. Therapeutic Advances in Endocrinology and Metabolism 10: 2042018819895462.
19. Koay YY, Tan GCJ, Phang SCW, Ho JI, Chuar PF, et al. (2021) A phase IIb randomized controlled trial investigating the effects of tocotrienol-rich vitamin E on diabetic kidney disease. Nutrients 13: 258.
20. Schelling JR (2022) The contribution of lipotoxicity to diabetic kidney disease. Cells 11: 3236.
21. Østergaard JA, Cooper ME, Jandeleit Dahm KAM (2020) Targeting oxidative stress and anti-oxidant defence in diabetic kidney disease. Journal of Nephrology 33: 917-929
22. Lee SR, An EJ, Kim J, Bae YS (2020) Function of NADPH oxidases in diabetic nephropathy and development of Nox inhibitors. Biomolecules & Therapeutics 28: 25-33.
23. Urner S, Ho F, Jha JC, Ziegler D, Jandeleit Dahm K, et al. (2020) NADPH oxidase inhibition Preclinical and clinical studies in diabetic complications. Antioxidants & Redox Signaling 33: 415-434.
24. Laddha AP, Kulkarni YA (2020) NADPH oxidase A membrane-bound enzyme and its inhibitors in diabetic complications. European Journal of Pharmacology 881: 173206.
25. Gupta A, Tapan Behl, Aayush Sehgal, Saurabh Bhatia, Dharmender Jaglan, et al. (2021) Therapeutic potential of Nrf-2 pathway in the treatment of diabetic neuropathy and nephropathy. Molecular Biology Reports, 48: 2761-2774.
26. Tanase DM, Gosav EM, Anton MI, Floria M, Isac PNS (2022) Oxidative stress and NRF2/KEAP1/ARE pathway in diabetic kidney disease: New perspectives. Biomolecules 12: 1227.
27. Khor BH, Tiong HC, Tan SC, Wong SK, Chin KY, et al. (2021) Effects of tocotrienols supplementation on markers of inflammation and oxidative stress A systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 16: e0255205.
28. Flemming N, Pernoud L, Forbes JM (2022) Mitochondrial dysfunction in individuals with diabetic kidney disease: A systematic review. Cells 11: 2481.
29. Baek J, Lee YH, Jeong HY, Lee SY (2023) Mitochondrial quality control and its emerging role in the pathogenesis of diabetic kidney disease. Kidney Research and Clinical Practice 42: 546-560.
30. Fan X, Yang M, Lang Y, Lu S, Kong Z, et al. (2024) 'Mitochondrial metabolic reprogramming in diabetic kidney disease. Cell Death & Disease 15: 442.
31. Narongkiatikhun P, Choi YJ, Hampson H, Gotzamanis J, Zhang G, et al. (2024) Unraveling diabetic kidney disease The roles of mitochondrial dysfunction and immunometabolism. Kidney International Reports 9: 3386-3402.
32. Yang Y, Liu J, Sh Q, Guo B, Jia H, et al. (2024) Roles of mitochondrial dysfunction in diabetic kidney disease New perspectives from mechanism to therapy. Biomolecules 14: 733.
33. Luo J, Lu F, Cuciureanu M, Xu X, Dong H, et al. (2026) Targeting mitochondrial quality control in diabetic kidney disease emerging therapeutic opportunities. Renal Failure 48: 2620218.
34. Sun H, Sun R, Hua Y, Lu Q, Shao X, et al. (2023) An update on the role of thioredoxin-interacting protein in diabetic kidney disease A mini review. Frontiers in Medicine 10: 1153805.
35. Khalid M, Petroianu G, Adem A (2022) Advanced glycation end products and diabetes mellitus Mechanisms and perspectives. Biomolecules 12: 542.
36. Fotheringham AK, Gallo LA, Borg DJ, Forbes JM (2022) Advanced glycation end products (AGEs) and chronic kidney disease Does the modern diet AGE the kidney?. Nutrients 14: 2675.
37. Donate Correa J, Ferri CM, Sánchez Quintana F, Pérez Castro A, González Luis A, et al. (2021) Inflammatory cytokines in diabetic kidney disease: Pathophysiologic and therapeutic implications. Frontiers in Medicine 7: 628289.
38. Jung SW, Moon JY (2021) The role of inflammation in diabetic kidney disease. Korean Journal of Internal Medicine 36: 753-766.
39. Williams BM, Cliff CL, Lee K, Squires PE, Hills CE, et al. (2022) The role of the NLRP3 inflammasome in mediating glomerular and tubular injury in diabetic nephropathy. Frontiers in Physiology 13: 907504.
40. Wan J, Liu D, Pan S, Zhou S, Liu Z, et al. (2022) NLRP3-mediated pyroptosis in diabetic nephropathy. Frontiers in Pharmacology 13: 998574.
41. Xu C, Ha X, Yang S, Tian X, Jiang H, et al. (2023) Advances in understanding and treating diabetic kidney disease Focus on tubulointerstitial inflammation mechanisms. Frontiers in Endocrinology 14: 1232790.
42. Lora Gil C, Hooker E, Larrivée B (2021) Diabetic kidney disease, endothelial damage and podocyte-endothelial crosstalk. Kidney Medicine 3: 105-115.
43. Yu H, Song YY, Li XH (2023) Early diabetic kidney disease Focus on the glycocalyx. World Journal of Diabetes 14: 460-480.
44. Jardine, M, Zien Zhou, Hiddo J Lambers Heerspink, Carinna Hockham, Qiang Li, et al. (2021) Kidney cardiovascular and safety outcomes of canagliflozin according to baseline albuminuria A CREDENCE secondary analysis. Clinical Journal of the American Society of Nephrology 16: 384-395.
45. Jardine MJ, Zien Zhou, Kenneth W Mahaffey, Megumi Oshima, Rajiv Agarwal, et al. (2020) Renal cardiovascular, and safety outcomes of canagliflozin by baseline kidney function A secondary analysis of the CREDENCE randomized trial. Journal of the American Society of Nephrology 31: 1128-1139.
46. Zou X, Qingyang Shi, Per Olav Vandvik, Yunhe Mao, Arnav Agarwal, et al. (2024) Sodium-glucose co-transporter-2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes Systematic review and meta-analysis. BMJ Medicine 3: e001009.
47. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, et al. (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease the FIDELITY pooled analysis. European Heart Journal 43: 474-484.

48. Rojano Toimil A, Ciudin A (2021) GLP-1 receptor agonists in diabetic kidney disease From physiology to clinical outcomes. Journal of Clinical Medicine 10: 3955.
49. MacIsaac RJ, Trevella P, Ekinci EI (2024) Glucagon-like peptide-1 receptor agonists and kidney outcomes. Journal of Diabetes 16: e13609.
50. Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, et al. (2025) Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes a meta-analysis of randomised controlled trials. The Lancet Diabetes & Endocrinology 13: 15-28.
51. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, et al. (2022) Management of hyperglycaemia in type 2 diabetes 2022 A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 65: 1925-1966.
52. American Diabetes Association Professional Practice Committee (2024) Chronic Kidney Disease and Risk Management Standards of Care in Diabetes-2024. Diabetes Care 47: S219-S230.
53. Mahjabeen W, Khan DA, Mirza SA, Pervez MA (2021) Effects of delta-tocotrienol supplementation on glycemic control, oxidative stress, inflammatory biomarkers and miRNA expression in type 2 diabetes mellitus A randomized control trial. Phytotherapy Research 35: 3968-3976.
54. Hou Y, Tan E, Shi H, Ren X, Wan X, et al. (2024) Mitochondrial oxidative damage reprograms lipid metabolism of renal tubular epithelial cells in the diabetic kidney. Cellular and Molecular Life Sciences 81: 23.
55. Sauriasari R, Safitri DD, Azmi NU (2021) Current updates on protein as biomarkers for diabetic kidney disease A systematic review. Therapeutic Advances in Endocrinology and Metabolism 12: 20420188211049612.
56. Gembillo G, Soraci L, Messina R, Lo Cicero L, Spadaro G, et al. (2026) Urinary biomarkers of diabetic kidney disease. World Journal of Diabetes 17: 110502.
57. Chen TK, Coca SG, Thiessen Philbrook HR, Heerspink HJL, Obeid W, et al. (2022b) Urinary biomarkers of tubular health and risk for kidney function decline or mortality in diabetes. American Journal of Nephrology 53: 775-785.
58. Gohda T, Nozomu Kamei, Mitsunobu Kubota, Kanako Tanaka, Yoshinori Yamashita , et al. (2021) Fractional excretion of tumor necrosis factor receptor 1 and 2 in patients with type 2 diabetes and normal renal function. Journal of Diabetes Investigation 12: 382-389.
59. Chen TK, Coca SG, Estrella MM, Appel LJ, Coresh J, et al. (2022a) Longitudinal TNFR1 and TNFR2 and kidney outcomes Results from AASK and VA NEPHRON-D. Journal of the American Society of Nephrology 33: 996-1010.
60. Sharif M, Khan DA, Farhat K, Noor M, Khan MA, et al. (2023) Pharmacokinetics and bioavailability of tocotrienols in healthy human volunteers A systematic review. Journal of the Pakistan Medical Association 73: 603-610.
61. EMPA KIDNEY Collaborative Group (2025) Long-term effects of empagliflozin in patients with chronic kidney disease. New England Journal of Medicine 392: 777-787.
62. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, et al . (2021) New creatinine- and cystatin C-based equations to estimate GFR without race. New England Journal of Medicine 385: 1737-1749.
63. Li D, Hsu FC, Palmer ND, Liu L, Choi YA, et al. (2024) Multiomics analyses identify AKR1A1 as a biomarker for diabetic kidney disease. Diabetes, 73: 1188-1195.
64. Hill C, McKnight AJ, Smyth LJ (2025) Integrated multiomic analyses An approach to improve understanding of diabetic kidney disease. Diabetic Medicine 42: e15447.

Copyright: ©2026 Loso Judijanto. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.